TABLE 1.
Demographics and baseline clinical variables of the subject in this study
| Analysis variablea | Efavirenz + NRTIs | Lopinavir- ritonavir + NRTIs | VPA without efavirenz or lopinavir |
|---|---|---|---|
| Mean age (yr), SD | 41.0, 5.3 | 45.4, 6.7 | 43.0, 7.7 |
| % of males | 81.8 | 81.8 | 83.3 |
| Ethnicity (%) | |||
| Caucasian | 45.4 | 63.6 | 66.7 |
| Black | 45.4 | 36.4 | 25.0 |
| Hispanic | 9.1 | 8.3 | |
| Karnofsky score of ≥80 (%) | 100.0 | 81.8 | 91.7 |
| History of HIV-related diagnoses (%) | 27.3 | 36.4 | 16.7 |
| Mean CD4 cell count/mm3, SD | 545.9, 214.0 | 416.7, 463.3 | 340.6, 232.9 |
| Antiretroviral use (%) | |||
| Abacavir | 55 | 55 | 36 |
| Didanosine | 18 | 27 | 0 |
| Lamivudine | 72 | 55 | 45 |
| Stavudine | 18 | 45 | 0 |
| Zalcitabine | 0 | 0 | 9 |
| Zidovudine | 36 | 27 | 36 |
| Indinavir | 0 | 0 | 9 |
| Amprenavir | 0 | 0 | 9 |
| Nevirapine | 0 | 0 | 9 |
| Nelfinavir | 0 | 0 | 9 |
a
The numbers of subjects included in the efavirenz plus NRTI, lopinavir-ritonavir plus NRTI, and VPA without efavirenz or lopinavir groups were 11, 11, and 12, respectively.